Clinical Trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Protocol Amendment History 2 changes
notable Trial sites expanded: 130 -> 133 locations 2026-05-09
notable Trial sites expanded: 125 -> 130 locations 2026-04-14
Trial Details
NCT Number NCT06727604
Lead Sponsor Immunovant Sciences GmbH
Conditions Graves' Disease
Enrollment 240 participants
Start Date 2024-12-17
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-11